Schizophrenia affects 1% of the global population and is caused by a complex interplay between at least 280 genes and ...
Helping patients navigate disability outside the clinic is critical to rehabilitation for physical conditions. People with ...
New research urges reclassifying schizophrenia as a neurodevelopmental syndrome—advancing diagnosis, care, and public ...
Researchers identified a protein biomarker linked to schizophrenia and developed a synthetic peptide that restores neural ...
US-based biopharmaceutical company Spinogenix has concluded the enrolment of patients in its Phase II clinical trial of tazbentetol (previously known as SPG302), a synaptic regenerative treatment for ...
A recent meta-analysis found that autistic individuals have a higher prevalence of these disorders (e.g., schizophrenia, schizoaffective, delusional), at 4%, than the general population, at 0.46%.[1][ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results